Physician profile
Michael E Etomi
NPI 1720039787
$212,400.71
in general payments reported to CMS, 2019-2025
22 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,105 · 2021: $16K · 2022: $37K · 2023: $38K · 2024: $31K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Honoraria: $27K · Travel and Lodging: $19K · Food and Beverage: $5,347 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,250.00 |
| Honoraria | $27,160.00 |
| Travel and Lodging | $18,928.34 |
| Food and Beverage | $5,347.09 |
| Education | $222.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87,056.16 | 2023-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $76,697.59 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $42,894.80 | 2020-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $2,538.73 | 2022-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $653.50 | 2019-2025 | |
| Gilead Sciences, INC. | $383.83 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $379.05 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $275.59 | 2019-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $225.49 | 2024-2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $188.19 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $166.38 | 2022-2023 | Onpattro, Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.73 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $134.80 | 2023-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $130.27 | 2019-2023 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $125.21 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $110.15 | 2019 | |
| Davol INC. | $92.39 | 2025 | Phasix Mesh |
| Akebia Therapeutics INC | $54.58 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $54.25 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.09 | 2025 | |
| Travere Therapeutics, INC. | $23.96 | 2023 | |
| Mallinckrodt Enterprises LLC | $17.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Etomi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.